We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 409.6999 -1.5286% AAPL 222.71 -1.8034% NVDA 128.3057 2.7103% GOOGL 163.14 -2.3465% GOOG 164.6592 -2.3142% AMZN 180.47 -3.2384% META 585.16 -1.8089% AVGO 175.79 -0.4812% TSLA 241.6955 -3.3527% TSM 183.57 1.3303% LLY 899.35 1.374% V 273.29 -1.6695% JPM 209.74 -0.7007% UNH 585.745 -0.9227% NVO 117.48 2.05% WMT 79.45 -1.8409% LVMUY 149.27 1.7519% XOM 125.47 0.5127% LVMHF 747.0 1.8335% MA 491.24 -1.298%

Amplia Therapeutics Limited

Healthcare US INNMF

0.11USD
-(-%)

Last update at 2024-10-04T13:30:00Z

Day Range

0.110.11
LowHigh

52 Week Range

0.030.10
LowHigh

Fundamentals

  • Previous Close 0.11
  • Market Cap10.62M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.51328M
  • Revenue TTM1.87M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 0.98M
  • Diluted EPS TTM-0.02

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -6.24244M -3.64422M -2.28100M -2.21900M -1.87000M
Minority interest - - - - -
Net income -6.24244M -3.64422M -2.28100M -2.21900M -1.87000M
Selling general administrative 2.41M 1.70M 1.35M 1.06M 1.05M
Selling and marketing expenses - - - - -
Gross profit - - - - -0.10500M
Reconciled depreciation 0.07M 0.00321M 0.00100M 0.00080M 0.00159M
Ebit -6.18859M -3.64307M -3.87400M -2.25700M -1.94100M
Ebitda -6.11522M -3.63986M -3.87300M -2.25600M -1.93900M
Depreciation and amortization 0.07M 0.00321M 0.00100M 0.00100M 0.00200M
Non operating income net other - - - - -
Operating income -6.18859M -3.64307M -3.87400M -2.25700M -1.94100M
Other operating expenses 7.48M 5.63M 3.87M 2.26M 1.94M
Interest expense 0.05M 0.00115M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.10M 0.00062M 0.00100M 0.00372M 0.02M
Net interest income 0.04M -0.00053M 0.00100M 0.00372M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.24M 1.98M -0.00100M -0.00400M -0.02000M
Total revenue - - - - 0.05M
Total operating expenses 7.48M 5.63M 3.87M 2.26M 1.94M
Cost of revenue - - - - 0.16M
Total other income expense net 1.19M 1.98M 1.59M 0.03M 0.05M
Discontinued operations - - - - -
Net income from continuing ops -6.24244M -3.64422M -2.28100M -2.21947M -1.86996M
Net income applicable to common shares -6.24244M -3.64422M -2.28115M -2.21947M -1.86996M
Preferred stock and other adjustments - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 18.68M 24.48M 10.88M 9.12M 9.19M
Intangible assets 7.94M 7.94M 7.94M 7.94M 7.94M
Earning assets - - - - -
Other current assets 0.07M 0.05M 1.09M 0.07M 0.01M
Total liab 2.85M 2.64M 0.54M 0.51M 0.53M
Total stockholder equity 15.84M 21.85M 10.34M 8.61M 8.66M
Deferred long term liab - - - - -
Other current liab 0.22M 0.16M 0.00113M -0.00038M -0.01076M
Common stock 151.53M 151.51M 136.55M 132.90M 130.95M
Capital stock 151.53M 151.51M 136.55M 132.90M 130.95M
Retained earnings -134.72442M -128.61845M -125.20600M -122.92500M -120.91800M
Other liab 0.00353M 0.00541M - - -
Good will - - - - -
Other assets 0.05M - - - -
Cash 9.26M 14.61M 1.85M 1.11M 1.24M
Cash and equivalents - - - - -
Total current liabilities 2.75M 0.53M 0.54M 0.51M 0.53M
Current deferred revenue - - - - -0.04390M
Net debt -6.98081M -12.50811M -1.84800M -1.10800M -1.23039M
Short term debt 2.18M - - - 0.01M
Short long term debt 2.11M - - - 0.01M
Short long term debt total 2.28M 2.10M - - 0.01M
Other stockholder equity -0.96903M -1.04165M -0.00004M -0.00023M -0.00052M
Property plant equipment 0.18M 0.01M 0.00547M 0.00080M 0.00160M
Total current assets 10.51M 16.53M 2.94M 1.18M 1.25M
Long term investments - - - - -
Net tangible assets 7.90M 13.91M 2.40M 0.67M 0.73M
Short term investments - - - - -
Net receivables 1.15M 1.84M 1.00M 0.03M -
Long term debt - 2.10M - - -
Inventory 0.04M 0.03M -0.99931M -0.03457M -
Accounts payable 0.35M 0.37M 0.54M 0.51M 0.53M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.96903M -1.04165M -1.00800M -1.37200M -1.36300M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.05M - 0.00040M -0.00027M -0.00047M
Deferred long term asset charges - - - - -
Non current assets total 8.18M 7.95M 7.94M 7.94M 7.94M
Capital lease obligations 0.17M - - - -
Long term debt total - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -0.05842M -0.01224M -0.01224M -0.01224M -0.01224M
Change to liabilities -0.01073M 0.00372M 0.03M -0.01624M 0.25M
Total cashflows from investing activities -0.05842M -0.02664M -0.00535M -0.00535M -0.00319M
Net borrowings -0.06465M 2.10M 2.10M 2.10M 2.10M
Total cash from financing activities -0.08422M 17.19M 3.66M 1.96M -0.01100M
Change to operating activities - - - - -
Net income -6.24244M -3.64422M -2.28115M -2.21947M -1.86996M
Change in cash -5.35190M 12.76M 0.74M -0.13300M -0.98800M
Begin period cash flow 14.61M 1.85M 1.11M 1.24M 2.23M
End period cash flow 9.26M 14.61M 1.85M 1.11M 1.24M
Total cash from operating activities -5.28969M -4.40202M -2.91626M -2.08798M -0.98735M
Issuance of capital stock 0.02M 16.27M 4.06M 2.15M -
Depreciation 0.07M 0.00321M 0.00067M 0.00080M 0.00159M
Other cashflows from investing activities -0.04079M -0.01224M -0.01224M -0.01224M -0.01224M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.68M -0.82543M -1.01837M -0.05865M 0.40M
Sale purchase of stock - -1.18186M -0.40200M -0.19200M -0.01100M
Other cashflows from financing activities -0.10545M 2.10M -0.00500M -0.19148M -0.00300M
Change to netincome 0.21M 0.06M 0.35M 0.21M 0.23M
Capital expenditures 0.02M 0.01M 0.00500M 0.00535M 0.00300M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - - - - -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow -0.01763M -0.01440M -0.00500M -2.08798M -0.00300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
INNMF
Amplia Therapeutics Limited		 - -% 0.11 - - 5.68 0.49 -1.3592
NVO
Novo Nordisk A/S		 2.36 2.05% 117.48 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.56 3.12% 117.60 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -5.645 1.24% 449.67 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -15.105 1.49% 997.72 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Amplia Therapeutics Limited

350 Queen Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. CEO, MD & Director 1964
Mr. Hamish George Chief Financial Officer NA
Ms. Rhiannon Jones B.Sc., Ph.D. Chief Operating Officer NA
Ms. Terrie-Anne Cock Ph.D. Head of Translational Biology NA
Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD Company Sec. 1960
Dr. Frank Gelder Founding Scientist NA
Dr. James A. Taylor Ph.D. Trials Consultant 1961
Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR Trials Consultant 1948
Dr. Benjamin M. Segal Clinical Consultant NA
Dr. Frederick E. Reno Ph.D. Toxicology Consultant NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.